Furthermore, in comparison to treatment with first-generation EGFR-TKIs (gefitinib or erlotinib), osimertinib had a higher rate of cardiac toxicity, manifesting in QT prolongation in 10% of patients who had received osimertinib compared with 4% of patients treated with EGFR-TKIs, and cardiac failure in 4% of patients treated with osimertinib and 2% with EGFR-TKIs (69). Here, EGFR is linked to heart failure.